KROS 8-K 2026-11-05

Keros Therapeutics, Inc. (KROS) 8-K dated 2026-11-05 — accession 0001664710-26-000065.

Keros Therapeutics, Inc. (KROS) is a biotechnology company listed on US.

Keros Therapeutics, Inc. filed a 8-K on 2026-11-05. Accession 0001664710-26-000065.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported KROS revenue for 2025-12-31 was $243.9M. Net income was $87.0M. KROS currently screens at market cap $208.8M.

Not investment advice. The KROS SEC hub lists recent forms. The stock page is the research view.